We'll see Dew. Management deserves what they are getting because they mispriced their drug into a marketplace in which it had 0% chance to succeed at that price point. Still boggles the mind they made that call. However, had they priced it perfectly and closer to where it is now, things still would have gone horribly IMO. Street wanted 250-300 million first year and that simply wasn't realistic, and was never going to happen, regardless of price. The fact that the pps is where it is now is more a consequence of that than anything. So the pps has nothing to do with a poor drug and everything to do with lack of confidence in management and disappointment over expectations that were never realistic to begin with. However, even if they make the right call in the future on that or other things, it is no guarantee of success is what I have learned. Many will resist Daxxify for many different reasons, and may or may not be honest about what they really are. Contrast to therapeutics is that your Doctor may or may not have your best interests in mind. Biggest problem is the consumer is not in control of their own outcome because they trust the practice to guide them. Throw in a toxic biotech market that is beyond a bear, and here we are
Market Data 
Markets 
AI
